BCAB News and Press, BioAtla Inc. From 03/01/22

BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS - Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim update expected in first quarter results conference call. NSCLC Phase 2 interim update expected in first half 2022. - Ozuriftamab vedotin (BA3...

BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors PR Newswire SAN DIEGO , Jan. 10, 2022 /PRNewswire/ ...

BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS PR Newswire SAN DIEGO , Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, t...

BioAtla (NASDAQ:BCAB): Q3 Net Loss of $22.9M Cash and cash equivalents as of September 30, 2021 were $269.9M Press Release For further details see: BioAtla reports Q3 results

BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical And Business Update - Mecbotamab vedotin (BA3011 ) sarcoma Phase 2 interim data read-out on-schedule for year end. Phase 1 sarcoma data presented at recent CTOS 2021 annual meeting - Mecbotamab vedo...

BTIG analyst Kaveri Pohlman assumed coverage of Replimune Group (NASDAQ:REPL) with a Buy rating and $60 price target (PT), implying a premium of ~93% from last close. The analyst assumed coverage of 10 more Immuno-oncology companies, and believes "much of the most promising work" involves bro...

LianBio, a Princeton, NJ-Shanghai biopharma, has filed for a $100 million IPO on the NASDAQ exchange. According to a Bloomberg article, I-Mab is in wide-ranging discussions with US and EU biopharmas for a deal that could out-license an I-Mab asset or involve a direct investment in the...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

BioAtla Announces Private Placement of 2.7 Million Shares Proceeds to advance CAB-AXL and CAB-ROR2 through potentially registration enabling Phase 2 clinical trials, and additional CAB development programs PR Newswire SAN DIEGO , Sept. 29, 2021 /PRNewswire/ -...

BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical Update $207.6 million cash balance expected to provide funding for operations into 2023 Continue to advance potentially registration enabling Phase 2 studies for mecbotamab vedotin (BA3011) and ozu...